Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Severe Neutropenia is Associated with Better Clinical Outcomes in Patients with Advanced Pancreatic Cancer Who Receive Modified FOLFIRINOX Therapy.

Yamada Y, Fujii H, Watanabe D, Kato-Hayashi H, Ohata K, Kobayashi R, Ishihara T, Uemura S, Iwashita T, Shimizu M, Suzuki A.

Cancers (Basel). 2018 Nov 16;10(11). pii: E454. doi: 10.3390/cancers10110454.

2.

Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial.

Nywening TM, Wang-Gillam A, Sanford DE, Belt BA, Panni RZ, Cusworth BM, Toriola AT, Nieman RK, Worley LA, Yano M, Fowler KJ, Lockhart AC, Suresh R, Tan BR, Lim KH, Fields RC, Strasberg SM, Hawkins WG, DeNardo DG, Goedegebuure SP, Linehan DC.

Lancet Oncol. 2016 May;17(5):651-62. doi: 10.1016/S1470-2045(16)00078-4. Epub 2016 Apr 4.

3.

High total bilirubin level is a significant risk factor for severe neutropenia in patients receiving irinotecan-based chemotherapy.

Yamada Y, Fujii H, Ohata K, Kato-Hayashi H, Watanabe D, Ishihara T, Uemura S, Iwashita T, Imai H, Matsuhashi N, Takahashi T, Sugiyama T, Shimizu M, Yoshida K, Suzuki A.

Med Oncol. 2019 Jun 3;36(7):63. doi: 10.1007/s12032-019-1288-7.

PMID:
31161433
4.

Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial.

Alistar A, Morris BB, Desnoyer R, Klepin HD, Hosseinzadeh K, Clark C, Cameron A, Leyendecker J, D'Agostino R Jr, Topaloglu U, Boteju LW, Boteju AR, Shorr R, Zachar Z, Bingham PM, Ahmed T, Crane S, Shah R, Migliano JJ, Pardee TS, Miller L, Hawkins G, Jin G, Zhang W, Pasche B.

Lancet Oncol. 2017 Jun;18(6):770-778. doi: 10.1016/S1470-2045(17)30314-5. Epub 2017 May 8.

5.

FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis.

Suker M, Beumer BR, Sadot E, Marthey L, Faris JE, Mellon EA, El-Rayes BF, Wang-Gillam A, Lacy J, Hosein PJ, Moorcraft SY, Conroy T, Hohla F, Allen P, Taieb J, Hong TS, Shridhar R, Chau I, van Eijck CH, Koerkamp BG.

Lancet Oncol. 2016 Jun;17(6):801-810. doi: 10.1016/S1470-2045(16)00172-8. Epub 2016 May 6. Review.

6.

The efficacy and safety of modified FOLFIRINOX as first-line chemotherapy for Chinese patients with metastatic pancreatic cancer.

Wang ZQ, Zhang F, Deng T, Zhang L, Feng F, Wang FH, Wang W, Wang DS, Luo HY, Xu RH, Ba Y, Li YH.

Cancer Commun (Lond). 2019 May 8;39(1):26. doi: 10.1186/s40880-019-0367-7.

7.

Folfirinox in elderly patients with pancreatic or colorectal cancer-tolerance and efficacy.

Guion-Dusserre JF, Bertaut A, Ghiringhelli F, Vincent J, Quipourt V, Marilier S, Tharin Z, Bengrine-Lefevre L.

World J Gastroenterol. 2016 Nov 14;22(42):9378-9386.

8.

Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer.

Stein SM, James ES, Deng Y, Cong X, Kortmansky JS, Li J, Staugaard C, Indukala D, Boustani AM, Patel V, Cha CH, Salem RR, Chang B, Hochster HS, Lacy J.

Br J Cancer. 2016 Mar 29;114(7):737-43. doi: 10.1038/bjc.2016.45.

9.

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardière C, Bennouna J, Bachet JB, Khemissa-Akouz F, Péré-Vergé D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M; Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup.

N Engl J Med. 2011 May 12;364(19):1817-25. doi: 10.1056/NEJMoa1011923.

10.

Efficacy of Prophylactic G-CSF in Patients Receiving FOLFIRINOX: A Preliminary Retrospective Study.

Terazawa T, Goto M, Miyamoto T, Asaishi K, Shimamoto F, Kuwakado S, Nishitani H, Kii T, Higuchi K.

Intern Med. 2015;54(23):2969-73. doi: 10.2169/internalmedicine.54.5325. Epub 2015 Dec 1.

11.

Phase II study of FOLFIRINOX for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer.

Okusaka T, Ikeda M, Fukutomi A, Ioka T, Furuse J, Ohkawa S, Isayama H, Boku N.

Cancer Sci. 2014 Oct;105(10):1321-6. doi: 10.1111/cas.12501. Epub 2014 Sep 29.

12.

5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma.

Assaf E, Verlinde-Carvalho M, Delbaldo C, Grenier J, Sellam Z, Pouessel D, Bouaita L, Baumgaertner I, Sobhani I, Tayar C, Paul M, Culine S.

Oncology. 2011;80(5-6):301-6. doi: 10.1159/000329803. Epub 2011 Jul 18.

PMID:
21778770
13.

A multicenter prospective phase II study of first-line modified FOLFIRINOX for unresectable advanced pancreatic cancer.

Yoshida K, Iwashita T, Uemura S, Maruta A, Okuno M, Ando N, Iwata K, Kawaguchi J, Mukai T, Shimizu M.

Oncotarget. 2017 Nov 30;8(67):111346-111355. doi: 10.18632/oncotarget.22795. eCollection 2017 Dec 19.

14.

Modified FOLFIRINOX for unresectable locally advanced/metastatic pancreatic cancer. A real-world comparison of an attenuated with a full dose in a single center experience.

Cavanna L, Stroppa EM, Citterio C, Mordenti P, Di Nunzio C, Peveri S, Orlandi E, Vecchia S.

Onco Targets Ther. 2019 Apr 23;12:3077-3085. doi: 10.2147/OTT.S200754. eCollection 2019.

15.

Effect of FOLFIRINOX as second-line chemotherapy for metastatic pancreatic cancer after gemcitabine-based chemotherapy failure.

Kobayashi N, Shimamura T, Tokuhisa M, Goto A, Endo I, Ichikawa Y.

Medicine (Baltimore). 2017 May;96(19):e6769. doi: 10.1097/MD.0000000000006769.

16.

Efficacy and Safety of FOLFIRINOX in Locally Advanced Pancreatic Cancer. A Single Center Experience.

Lakatos G, Petranyi A, Szűcs A, Nehéz L, Harsanyi L, Hegyi P, Bodoky G.

Pathol Oncol Res. 2017 Oct;23(4):753-759. doi: 10.1007/s12253-016-0176-0. Epub 2017 Jan 6.

PMID:
28062950
17.

Comparison of efficacy and toxicity of FOLFIRINOX and gemcitabine with nab-paclitaxel in unresectable pancreatic cancer.

Muranaka T, Kuwatani M, Komatsu Y, Sawada K, Nakatsumi H, Kawamoto Y, Yuki S, Kubota Y, Kubo K, Kawahata S, Kawakubo K, Kawakami H, Sakamoto N.

J Gastrointest Oncol. 2017 Jun;8(3):566-571. doi: 10.21037/jgo.2017.02.02.

18.

[Analysis on safety and preliminary efficacy of dose-modified regimen of 5-fluorouracil plus oxaliplatin and irinotecan (FOLFOXIRI) in advanced colorectal cancer].

Cai Y, Deng R, Hu H, Zhang J, Ling J, Wu Z, Yang L, Li J, Deng Y.

Zhonghua Wei Chang Wai Ke Za Zhi. 2018 Sep 25;21(9):1045-1050. Chinese.

PMID:
30269326
19.

5-Fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with advanced pancreatic cancer who have progressed on gemcitabine-based therapy.

Lee MG, Lee SH, Lee SJ, Lee YS, Hwang JH, Ryu JK, Kim YT, Kim DU, Woo SM.

Chemotherapy. 2013;59(4):273-9. doi: 10.1159/000356158. Epub 2014 Jan 18.

PMID:
24457620
20.

Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer--a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study.

Conroy T, Paillot B, François E, Bugat R, Jacob JH, Stein U, Nasca S, Metges JP, Rixe O, Michel P, Magherini E, Hua A, Deplanque G.

J Clin Oncol. 2005 Feb 20;23(6):1228-36.

PMID:
15718320

Supplemental Content

Support Center